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A genome-wide association study was performed using the
Affymetrix 6.0 chip to identify genes associated with diabetic
nephropathy in African Americans. Association analysis was
performed adjusting for admixture in 965 type 2 diabetic
African American patients with end-stage renal disease
(ESRD) and in 1029 African Americans without type 2
diabetes or kidney disease as controls. The top 724
single nucleotide polymorphisms (SNPs) with evidence of
association to diabetic nephropathy were then genotyped
in a replication sample of an additional 709 type 2
diabetes-ESRD patients and 690 controls. SNPs with evidence
of association in both the original and replication studies
were tested in additional African American cohorts consisting
of 1246 patients with type 2 diabetes without kidney disease
and 1216 with non-diabetic ESRD to differentiate candidate
loci for type 2 diabetes-ESRD, type 2 diabetes, and/or
all-cause ESRD. Twenty-five SNPs were significantly
associated with type 2 diabetes-ESRD in the genome-wide
association and initial replication. Although genome-wide
significance with type 2 diabetes was not found for any of
these 25 SNPs, several genes, including RPS12, LIMK2, and
SFI1 are strong candidates for diabetic nephropathy.
A combined analysis of all 2890 patients with ESRD showed
significant association SNPs in LIMK2 and SFI1 suggesting
that they also contribute to all-cause ESRD. Thus, our results
suggest that multiple loci underlie susceptibility to kidney
disease in African Americans with type 2 diabetes and some
may also contribute to all-cause ESRD.
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Diabetes-associated nephropathy is the most common cause of
end-stage renal disease (ESRD) in the United States, accounting
for 44.6% of incident cases.1 African Americans (AAs) have a
disproportionately high risk for developing diabetic nephro-
pathy (DN). Compared with Caucasian Americans (CAs), AAs
have a 3.7-fold greater incidence rate of developing ESRD and
at least a 1.9-fold greater incidence rate than do other racial
and ethnic minorities in the United States.1 Many studies have
shown that there is a genetic component to ESRD as reviewed
by Bowden.2 Familial aggregation of DN and diabetic ESRD
has been demonstrated in CAs3–5 and AAs.6 Clustering occurred
in these families without significant differences in glycemic
control.4 However, marked racial and ethnic disparities in
familial clustering exist. CAs who have a close relative with
ESRD face a 2.7-fold increased risk of developing ESRD,5
whereas AAs who have a close relative with ESRD have a
9-fold increased risk of developing ESRD.6 This significant
difference in rates of renal complications between CAs and
AAs is observed after controlling for differences in socio-
economic status.5,6
Several studies have attempted to detect genetic variants
influencing the risk of DN and diabetic ESRD. The first
genome-wide association study (GWAS) for DN was a low-
density (80K single-nucleotide polymorphisms (SNPs))
gene-based study performed in a Japanese population.7 This
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was followed by a study using a DNA pooling method
investigating 115K SNPs in Pima Indians with DN.8 More
recently, a GWAS was conducted for type 1 diabetes-
associated nephropathy in a CA population,9 and multiple
studies have assessed for association with chronic kidney
disease and glomerular filtration rate in nondiabetic popula-
tions of European ancestry.10–12 There have been no previous
reports of GWASs in AAs with type 2 diabetes mellitus
(T2DM)-ESRD. In this study, we report the first GWAS
investigating 832K SNPs for association with T2DM-ESRD
in AAs.
RESULTS
Clinical characteristics of study samples
The clinical characteristics of study samples used in the
GWAS, replication, and trait discrimination phases are
shown in Table 1. The GWAS and replication populations
are broadly similar. In both groups, the age at enrollment for
T2DM-ESRD subjects is older than that for the control
groups. However, the age at enrollment for the control
groups in the GWAS and replication phases is older than the
age of T2DM diagnosis in T2DM-ESRD and T2DM subjects.
All of the case groups with T2DM (T2DM-ESRD and T2DM)
have a higher proportion of females, possibly reflecting the
increased prevalence of T2DM among AA women,13
participation bias, and survival. On average, all of the groups
were overweight or obese at the time of enrollment. Subjects
with ESRD lacking T2DM (non-T2DM-ESRD subjects) had
the lowest average body mass index (27.0 kg/m2, Table 1),
and T2DM subjects without nephropathy (T2DM) had the
highest average body mass index (33.5 kg/m2, Table 1).
Genome-wide association study
After the application of SNP and sample quality control
metrics, 832,357 autosomal SNPs were analyzed in 965 AA
T2DM-ESRD case subjects and in 1029 AA nondiabetic,
nonnephropathy controls. A summary of the association
results is shown in Figure 1 and the corresponding
quantile–quantile plot is shown in Supplementary Figure S1
online. The results shown are adjusted for admixture;
however, the primary inferences remain the same adjusting
for admixture, age, and gender. The top hit was rs5750250
located on chromosome 22 in the MYH9 (nonmuscle myosin
heavy chain 9) gene (P¼ 3.00 107, Figure 1). This gene
has been previously associated with both nondiabetic and
diabetic forms of ESRD.14–17 In total, there were 126 SNPs
with P-values o1.0 104 (Figure 1). The flow of the study
through the GWAS, replication, combined and trait dis-
crimination phases is outlined in Table 2.
Replication and combined analysis of T2DM-ESRD cases and
nondiabetic, nonnephropathy controls
In an effort to replicate the GWAS results, 724 top-scoring
SNPs were genotyped in an independent sample of 709 AA
T2DM-ESRD cases and 690 AA nondiabetic, nonnephrop-
athy controls (study design, Table 2; Results, Supplementary
Table S1 online). The 724 SNPs that were selected for testing
in the replication sample were SNPs with the strongest
P-values for association and with high quality scores for
genotyping, that is, missing rate o0.02 (or missing rate
o0.05, but the missing rate between cases and controls was
not significantly different). In addition, P-values for Hardy–
Weinberg proportions were 40.0001 for cases and 40.01
for controls. SNPs were prioritized on significance of the
additive genetic model unless there was a priori evidence for
follow-up, for example, MYH9. In this replication analysis, 67
SNPs showed nominal evidence of replication: additive
P-value o0.05 with association in the same direction
(Supplementary Table S1 online). Table 3 summarizes the
association results for 25 SNPs at 19 potential T2DM-ESRD
loci. T2DM-ESRD loci were identified during trait discrimi-
nation analyses as shown in Table 2 and were based on the
following criteria: (1) associated in the replication phase, (2)
associated in the T2DM-ESRD versus T2DM, nonnephro-
pathy comparison (Table 4), and (3) showed no association or
nominal association (P40.01) in the T2DM, nonnephro-
pathy versus controls comparison (Table 4). Table 3 shows P-
values for association in the GWAS, the replication sample,
and the combined cohort: 1674 T2DM-ESRD cases and 1719
nondiabetic, nonnephropathy controls. No SNP reached
genome-wide significance (Pp5 108), P-values ranged
from 1.24 104 to 7.04 107 (Table 3, combined analysis).
The strongest association in the combined analysis
(GWASþ replication) was with rs6930576 (P¼ 7.04 107,
odds ratio (OR) (95% confidence interval (95% CI))¼ 1.31
(1.18–1.45); Table 3, Supplementary Figure S2a online). SNP
Table 1 | Clinical characteristics of study samples
GWAS Replication Trait discrimination
T2DM-ESRD Controls T2DM-ESRD Controls T2DM Non-T2DM-ESRD
n 965 1029 709 690 1246 1216
Female (%) 61.20 57.30 55.70 51.30 64.00 44.70
Age at enrollment (years) 61.6±10.5 49.0±11.9 60.2±10.4 48.5±12.8 57.2±11.7 53.0±14.5
Age at T2D diagnosis (years) 41.6±12.4 — 39.4±12.5 — 46.1±12.6 —
Age at ESRD diagnosis (years) 58.0±10.9 — 56.7±10.9 — — 47.7±15.5
T2D to ESRD duration (years) 16.2±10.9 — 20.4±10.5 — — —
BMI (kg/m2) 29.7±7.0 30.0±7.0 29.8±6.9 29.4±7.6 33.5±7.6 27.0±7.0
Abbreviations: BMI, body mass index; ESRD, end-stage renal disease; GWAS, genome-wide association study; T2DM, type 2 diabetes mellitus.
Values are presented as trait mean and s.d.
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rs6930576 is located in intron 1 of the SAM and SH3 domain
containing 1 (SASH1) gene. Six other hits were detected in
four regions with combined P-values o1.0 105. SNP
rs7769051 is located 8 kb upstream of the ribosomal S12
(RPS12) gene (P¼ 2.2 106, OR (95% CI)¼ 1.28
(1.16–1.42); Table 3, Supplementary Figure S2b online).
SNP rs773506 (P¼ 6.45 106, OR (95% CI)¼ 0.76
(0.67–0.85); Table 3, Supplementary Figure S2c online) is
located 600 bp 30 of AUH (AU RNA-binding protein/enoyl-
Coenzyme A). Next, SNP rs2358944 (P¼ 3.54 106, OR
(95% CI)¼ 0.75 (0.67–0.85); Table 3, Supplementary
Figure S2d online) is located 38 kb from the noncoding
RNA, ribosomal protein SA pseudogene 52 (RPSAP52). This
SNP, rs2358944, is also located near two coding genes:
HMGA2, high mobility group AT-hook 2 (101 kb upstream
of the variant), and MSRB3, methionine sulfoxide reductase
B3 (257 kb downstream of the marker). Finally, three hits
were located in the LIMK2 (LIM domain kinase 2) —SFI1
(Sfi1 homolog, spindle assembly-associated (yeast)) region:
rs2106294 and rs4820043 are both located in intron 2 of
LIMK2 (P¼ 4.11 106 and P¼ 5.07 106, OR (95%
CI)¼ 0.57 (0.45–0.72) and OR (95% CI)¼ 0.57 (0.45–0.73),
respectively; Table 3, Supplementary Figure S2e online), and
rs5749286 is located in intron 1 of SFI1 (P¼ 9.79 106, OR
(95% CI)¼ 0.60 (0.47–0.75); Table 3, Supplementary Figure
S2e online). The MYH9 SNP seen in the initial GWAS,
rs5750250, did not replicate (P¼ 0.0594, Supplementary
Table S2 online) and had a combined P-value of 1.66 107
(Supplementary Table S2 online).
Discrimination between T2DM-ESRD, T2DM, and all-cause
ESRD
The 67 SNPs that showed evidence of replication between
T2DM-ESRD cases and nonnephropathy, nondiabetic con-
trols were genotyped in an additional 1246 AA T2DM,
nonnephropathy cases and 1216 non-T2DM-ESRD cases to
differentiate between T2DM-ESRD, T2DM, and all-cause
ESRD loci (Table 2; results shown in Supplementary Table S3
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Figure 1 |Genome-wide association study results. The top hit was rs5750250 located on chromosome 22 in the MYH9 gene
(P¼ 3.00 107). Results are adjusted for admixture using PC1 as a covariate in the analysis. P-values are shown under the additive model.
Chr, chromosome; MYH9, nonmuscle myosin heavy chain 9; PC1, first principal component.
Table 2 | Study design and progression
Sample
Step Stage Total Cases Controls Description
1 GWAS 1994 965 T2DM-ESRD cases 1029 nondiabetic,
nonnephropathy controls
GWAS scan with 832,357 SNPs
2 Replication 1399 709 T2DM-ESRD cases 690 nondiabetic,
nonnephropathy controls
Test 724 SNPs from step 1 for replication
3 Combined analysis
(GWAS+replication)
3393 1674 T2DM-ESRD cases 1719 nondiabetic,
nonnephropathy controls
Identify SNPs with the strongest evidence of
association with T2DM-ESRD
4 Trait discrimination test
for T2DM or T2DM-ESRD
2920 1674 T2DM-ESRD cases 1246 T2DM (lacking
nephropathy) cases
Test 67 SNPs from step 3 to differentiate
between T2DM-ESRD and T2DM loci
5 Test for non-T2DM-ESRD 2935 1216 non-T2DM-ESRD cases 1719 nondiabetic,
nonnephropathy controls
Test 67 SNPs from step 3 for association with
all-cause ESRD
6 Test for all-cause ESRD 4609 2890 ESRD cases (1674
T2DM-ESRD and 1216
non-T2DM-ESRD)
1719 nondiabetic,
nonnephropathy controls
Test 67 SNPs from step 3 for association with
all-cause ESRD in the largest sample set
Abbreviations: ESRD, end-stage renal disease; GWAS, genome-wide association study; SNP, single-nucleotide polymorphism; T2DM, type 2 diabetes mellitus.
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Table 3 | Diabetic nephropathy candidate loci
Locus
GWAS T2DM-ESRD (n=965)
controls (n=1029)
Replication T2DM-ESRD (n=709)
controls (n=690)
Combined T2DM-ESRD (n=1674)
controls (n=1719)
Marker Chr. Position
Nearest
gene(s)
Minor allele
(major allele)
MAF
T2DM-ESRD
MAF
controls
Additive
P-value
MAF
T2DM-ESRD
MAF
controls
Additive
P-value
Additive
P-value OR (95% CI)
rs10888287 1 246,184,039 OR2L13 G(T) 0.439 0.503 5.03E-04 0.444 0.495 0.0482 5.97E-05 0.82 (0.75–0.90)
rs4260465 3 164,231,046 No gene G(C) 0.364 0.414 4.31E-04 0.381 0.421 0.0382 4.50E-05 0.81 (0.74–0.90)
rs11730446 4 96,382,267 UNC5C G(A) 0.459 0.403 6.23E-04 0.459 0.424 0.0465 1.24E-04 1.21 (1.10–1.33)
rs891382 4 147,371,790 SLC10A7/LSM6 G(A) 0.085 0.059 3.19E-04 0.081 0.065 0.0183 2.42E-05 1.49 (1.24–1.80)
rs7697691 4 182,853,951 No gene G(A) 0.243 0.285 0.0016 0.243 0.285 0.0127 7.37E-05 0.80 (0.72–0.89)
rs3822908 6 97,706,333 C6orf167 C(T) 0.125 0.162 3.63E-04 0.121 0.147 0.0462 4.52E-05 0.75 (0.65–0.86)
rs7760831 6 102,071,536 GRIK2 C(T) 0.176 0.222 2.55E-04 0.193 0.224 0.0455 3.48E-05 0.77 (0.69–0.87)
rs208865 6 130,114,249 C6orf191/ARHGAP18 T(C) 0.118 0.082 2.14E-04 0.115 0.091 0.0364 2.90E-05 1.41 (1.20–1.66)
rs9493454 6 133,186,322 RPS12 C(A) 0.439 0.376 4.91E-04 0.453 0.395 0.0089 1.72E-05 1.24 (1.13–1.37)
rs7769051 6 133,188,489 RPS12 A(C) 0.349 0.289 4.06E-04 0.362 0.3 0.0012 2.20E-06 1.28 (1.16–1.42)
rs6930576 6 148,746,647 SASH1 A(G) 0.337 0.276 1.87E-05 0.319 0.274 0.0099 7.04E-07 1.31 (1.18–1.45)
rs773506 9 93,015,292 AUH A(G) 0.179 0.233 3.27E-04 0.174 0.223 0.0130 6.45E-06 0.76 (0.67–0.85)
rs11175885 12 64,400,897 C12orf66/TMEM5 G(A) 0.181 0.234 0.0013 0.19 0.249 0.0106 2.18E-05 0.77 (0.68–0.87)
rs2358944 12 64,403,825 MSRB3/HMGA2 A(G) 0.178 0.232 9.48E-04 0.188 0.256 0.0018 3.54E-06 0.75 (0.67–0.85)
rs2904532 12 65,582,311 GRIP1/CAND1 G(A) 0.141 0.183 8.17E-04 0.148 0.184 0.0172 4.87E-05 0.76 (0.67–0.87)
rs11176482 12 65,582,814 GRIP1/CAND1 C(T) 0.141 0.184 7.08E-04 0.147 0.182 0.0202 4.79E-05 0.76 (0.67–0.87)
rs12302041 12 76,654,356 NAV3 A(G) 0.085 0.055 3.09E-04 0.088 0.06 0.0149 1.15E-05 1.54 (1.27–1.87)
rs1978243 14 86,596,160 No gene T(C) 0.22 0.274 7.53E-04 0.221 0.274 0.0105 1.61E-05 0.78 (0.70–0.87)
rs6494387 15 61,132,579 TPM1 A(G) 0.367 0.311 2.32E-04 0.358 0.32 0.0209 1.80E-05 1.25 (1.13–1.39)
rs1034589 22 29,909,233 RNF185 C(T) 0.036 0.062 0.0010 0.033 0.065 0.0055 1.06E-05 0.59 (0.46–0.74)
rs2106294 22 29,975,759 LIMK2 C(T) 0.035 0.062 7.49E-04 0.031 0.064 0.0028 4.11E-06 0.57 (0.45–0.72)
rs4820043 22 29,977,094 LIMK2 A(G) 0.036 0.062 0.0010 0.031 0.065 0.0026 5.07E-06 0.57 (0.45–0.73)
rs5749286 22 30,230,359 SFI1 A(C) 0.038 0.065 0.0013 0.036 0.068 0.0030 9.79E-06 0.60 (0.47–0.75)
rs16996381 22 34,841,225 APOL3 G(A) 0.336 0.391 0.0018 0.371 0.432 0.0191 1.06E-04 0.82 (0.75–0.91)
rs735853 22 35,009,161 MYH9 G(C) 0.082 0.123 4.59E-04 0.079 0.118 0.0091 1.20E-05 0.69 (0.59–0.82)
Abbreviations: Chr., chromosome; ESRD, end-stage renal disease; GWAS, genome-wide association study; MAF, minor allele frequency; OR, odds ratio; T2DM, type 2 diabetes
mellitus; 95% CI, 95% confidence interval.
GWAS, replication, and combined (GWAS+replication) P-values for diabetic nephropathy candidate loci across the genome.
Table 4 | Diabetic nephropathy candidate loci: trait discrimination
Locus T2DM-ESRD (n=1674) versus T2DM (n=1246) T2DM (n=1246) versus controls (n=1719)
Marker Chr. Position Nearest gene(s) Additive P-value OR (95% CI) Additive P-value OR (95% CI)
rs10888287 1 246,184,039 OR2L13 0.0361 0.89 (0.80–0.99) 0.1487 0.93 (0.84–1.03)
rs4260465 3 164,231,046 No gene 2.63E-05 0.80 (0.72–0.89) 0.5177 1.03 (0.93–1.15)
rs11730446 4 96,382,267 UNC5C 0.0068 1.16 (1.04–1.29) 0.3319 1.05 (0.95–1.17)
rs891382 4 147,371,790 SLC10A7/LSM6 1.86E-04 1.49 (1.21–1.83) 0.8984 1.01 (0.82–1.25)
rs7697691 4 182,853,951 No gene 0.0046 0.84 (0.75–0.95) 0.3664 0.95 (0.84–1.07)
rs3822908 6 97,706,333 C6orf167 0.0336 0.84 (0.72–0.99) 0.1979 0.91 (0.78–1.05)
rs7760831 6 102,071,536 GRIK2 0.0494 0.87 (0.76–1.00) 0.0587 0.88 (0.78–1.00)
rs208865 6 130,114,249 C6orf191/ARHGAP18 0.0220 1.23 (1.03–1.46) 0.1259 1.15 (0.96–1.37)
rs9493454 6 133,186,322 RPS12 8.79E-04 1.20 (1.08–1.34) 0.5079 1.04 (0.93–1.16)
rs7769051 6 133,188,489 RPS12 0.0036 1.18 (1.06–1.32) 0.1614 1.09 (0.97–1.22)
rs6930576 6 148,746,647 SASH1 0.0053 1.18 (1.05–1.32) 0.0621 1.12 (0.99–1.25)
rs773506 9 93,015,292 AUH 2.57E-04 0.78 (0.69–0.89) 0.7484 0.98 (0.87–1.11)
rs11175885 12 64,400,897 C12orf66/TMEM5 0.0226 0.86 (0.75–0.98) 0.1068 0.90 (0.79–1.02)
rs2358944 12 64,403,825 MSRB3/HMGA2 0.0047 0.83 (0.72–0.94) 0.1532 0.91 (0.80–1.03)
rs2904532 12 65,582,311 GRIP1/CAND1 0.0047 0.81 (0.71–0.94) 0.3862 0.94 (0.82–1.08)
rs11176482 12 65,582,814 GRIP1/CAND1 0.0070 0.82 (0.71–0.95) 0.3052 0.93 (0.81–1.07)
rs12302041 12 76,654,356 NAV3 0.0226 1.27 (1.03–1.55) 0.0924 1.21 (0.97–1.50)
rs1978243 14 86,596,160 No gene 0.0332 0.87 (0.77–0.99) 0.0743 0.90 (0.79–1.01)
rs6494387 15 61,132,579 TPM1 0.0155 1.15 (1.03–1.29) 0.1683 1.08 (0.97–1.21)
rs1034589 22 29,909,233 RNF185 0.0274 0.74 (0.57–0.97) 0.0438 0.79 (0.63–0.99)
rs2106294 22 29,975,759 LIMK2 0.0167 0.72 (0.55–0.94) 0.0411 0.79 (0.63–0.99)
rs4820043 22 29,977,094 LIMK2 0.0162 0.72 (0.55–0.94) 0.0460 0.79 (0.63–1.00)
rs5749286 22 30,230,359 SFI1 0.0274 0.75 (0.58–0.97) 0.0344 0.78 (0.62–0.98)
rs16996381 22 34,841,225 APOL3 1.76E-04 0.82 (0.74–0.91) 0.8152 1.01 (0.91–1.12)
rs735853 22 35,009,161 MYH9 8.57E-04 0.73 (0.61–0.88) 0.4515 0.94 (0.80–1.11)
Abbreviations: Chr., chromosome; ESRD, end-stage renal disease; OR, odds ratio; T2DM, type 2 diabetes mellitus; 95% CI, 95% confidence interval.
Comparison of T2DM-ESRD versus T2DM, nonnephropathy subjects and T2DM, nonnephropathy subjects versus nondiabetic normal controls in diabetic nephropathy
candidate loci across the genome.
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online). Thus, T2DM-ESRD SNPs should have allele
frequency differences when compared with cases with
T2DM alone (lacking nephropathy). When the 25 T2DM-
ESRD candidate SNPs were compared between T2DM-ESRD
cases and T2DM subjects without nephropathy, there were
significant differences between these two groups (P-values
ranging from 0.049 to 2.63 105, Table 4), suggesting that
these are T2DM-ESRD loci rather than T2DM loci. SNPs in
RPS12 (rs9493454) and AUH (rs7735506) were still strongly
associated in this test (P¼ 8.79 104 and P¼ 2.57 104,
OR (95% CI)¼ 1.20 (1.08–1.34) and OR (95% CI)¼ 0.78
(0.69–0.89), respectively; Table 4).
As a second test, allele frequencies of these 25 SNPs in
T2DM, nonnephropathy subjects were compared with those
in normal, nondiabetic, nonnephropathy controls (Table 4;
control data from the GWAS and replication control
samples). True T2DM loci would be expected to show
evidence of association in this analysis. Although the four
SNPs in the LIMK2-SFI1 region (namely rs1034589,
rs2106294, rs4820043, and rs5749286) showed nominal
evidence of association with P-values ranging from 0.034 to
0.046 (OR ranging from 0.78 to 0.79, Table 4), these P-values
are orders of magnitude lower than comparing T2DM-
ESRD with controls (Table 3; combined analysis). This
further supports these SNPs as T2DM-ESRD loci and not as
T2DM loci.
The 25 SNPs were also investigated for association with
all-cause ESRD. In this analysis, cases consisted of 1674
T2DM-ESRD subjects (from the GWAS and replication
phases) and 1216 nondiabetic ESRD subjects (predominantly
ESRD attributed to hypertension and chronic glomerular
diseases). These 2890 cases with ESRD were compared with
the combined set of nondiabetic, nonnephropathy controls
(n¼ 1719, from the GWAS and replication phases). Five
variants in two genomic regions achieved genome-wide
significance in this analysis (Pp5.0 108, Table 5). The
LIMK2-SFI1 region contained four of these SNPs. First,
rs1034589, located in ring finger protein 185 (RNF185), was
associated with all-cause ESRD (P¼ 2.49 108, OR (95%
CI)¼ 0.56 (0.46–0.69); Table 5, Figure 2a). Two SNPs showed
evidence of association in the LIMK2 gene, namely rs2106294
and rs4820043 (P¼ 3.28 108 and P¼ 3.04 108, OR
(95% CI)¼ 0.56 (0.46–0.69) and OR (95% CI)¼ 0.56
(0.46–0.69), respectively; Table 5, Figure 2a). The last SNP
that was significantly associated in this region was rs5749286,
located in SFI1 (P¼ 2.96 1011, OR (95% CI)¼ 0.51
(0.41–0.62); Table 5, Figure 2a). Finally, SNP rs735853, in
MYH9 was also significantly associated with all-cause ESRD
(P¼ 4.77 1010, OR (95% CI)¼ 0.63 (0.54–0.73); Table 5,
Figure 2b). All markers were also examined for association
with nondiabetic ESRD compared with controls (Table 5;
control data from the GWAS and replication control
samples). In all, 12 markers showed association with
nondiabetic ESRD (P-values ranging from 0.0364 to
1.97 1010, ORs ranging from 0.38 to 0.86 and from 1.15
to 1.31, Table 5). However, all of these variants were more
Table 5 | Diabetic nephropathy candidate loci: all-cause ESRD
Locus All-cause ESRD (n=2890) versus controls (n=1719) non-T2DM-ESRD (n=1216) versus controls (n=1719)
Marker Chr. Position Nearest gene(s) Additive P-value OR (95% CI) Additive P-value OR (95% CI)
rs10888287 1 246,184,039 OR2L13 5.53E-05 0.84 (0.77–0.91) 0.0057 0.86 (0.78–0.96)
rs4260465 3 164,231,046 No gene 0.0027 0.88 (0.81–0.96) 0.4548 0.96 (0.87–1.07)
rs11730446 4 96,382,267 UNC5C 8.25E-05 1.19 (1.09–1.30) 0.0085 1.15 (1.04–1.28)
rs891382 4 147,371,790 SLC10A7/LSM6 2.56E-04 1.37 (1.16–1.63) 0.0859 1.20 (0.97–1.48)
rs7697691 4 182,853,951 No gene 0.0036 0.87 (0.79–0.95) 0.6059 0.97 (0.86–1.09)
rs3822908 6 97,706,333 C6orf167 2.43E-04 0.80 (0.71–0.90) 0.0364 0.85 (0.73–0.99)
rs7760831 6 102,071,536 GRIK2 1.62E-06 0.77 (0.69–0.86) 1.43E-04 0.77 (0.68–0.88)
rs208865 6 130,114,249 C6orf191/ARHGAP18 2.60E-05 1.37 (1.18–1.59) 0.0025 1.31 (1.10–1.56)
rs9493454 6 133,186,322 RPS12 2.35E-05 1.21 (1.11–1.32) 0.2134 1.07 (0.96–1.19)
rs7769051 6 133,188,489 RPS12 5.85E-06 1.24 (1.13–1.36) 0.1958 1.07 (0.96–1.19)
rs6930576 6 148,746,647 SASH1 4.76E-07 1.27 (1.16–1.40) 4.80E-04 1.23 (1.09–1.38)
rs773506 9 93,015,292 AUH 1.40E-04 0.82 (0.73–0.91) 0.0901 0.89 (0.79–1.02)
rs11175885 12 64,400,897 C12orf66/TMEM5 3.66E-04 0.83 (0.75–0.92) 0.1247 0.90 (0.80–1.03)
rs2358944 12 64,403,825 MSRB3/HMGA2 1.15E-04 0.82 (0.74–0.90) 0.1100 0.90 (0.79–1.02)
rs2904532 12 65,582,311 GRIP1/CAND1 4.13E-04 0.82 (0.73–0.91) 0.0902 0.89 (0.77–1.02)
rs11176482 12 65,582,814 GRIP1/CAND1 N/A N/A N/A N/A
rs12302041 12 76,654,356 NAV3 1.87E-04 1.40 (1.17–1.67) 0.0895 1.21 (0.97–1.51)
rs1978243 14 86,596,160 No gene 6.25E-04 0.84 (0.76–0.93) 0.2588 0.93 (0.83–1.05)
rs6494387 15 61,132,579 TPM1 0.0017 1.16 (1.06–1.27) 0.4478 1.04 (0.93–1.17)
rs1034589 22 29,909,233 RNF185 2.49E-08 0.56 (0.46–0.69) 2.17E-06 0.52 (0.40–0.68)
rs2106294 22 29,975,759 LIMK2 3.28E-08 0.56 (0.46–0.69) 7.15E-06 0.54 (0.42–0.71)
rs4820043 22 29,977,094 LIMK2 3.04E-08 0.56 (0.46–0.69) 5.77E-06 0.54 (0.41–0.70)
rs5749286 22 30,230,359 SFI1 6.51E-11 0.51 (0.41–0.62) 1.97E-10 0.38 (0.28–0.51)
rs16996381 22 34,841,225 APOL3 2.96E-07 0.80 (0.73–0.87) 7.20E-07 0.76 (0.69–0.85)
rs735853 22 35,009,161 MYH9 4.77E-10 0.63 (0.54–0.73) 7.76E-10 0.55 (0.45–0.66)
Abbreviations: Chr., chromosome; ESRD, end-stage renal disease; N/A, not applicable; OR, odds ratio; T2DM, type 2 diabetes mellitus; 95% CI, 95% confidence interval.
SNP rs11176482 failed to type in non-T2DM-ESRD subjects.
Comparison of all-cause ESRD (1674 T2DM-ESRD cases and 1216 non-T2DM-ESRD cases) with controls (combined from GWAS+replication), and non-T2DM-ESRD cases
with controls.
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strongly associated in the test of all-cause ESRD (Table 5),
and only four of these markers (rs1034589, rs5749286,
rs16996381, and rs735853) showed stronger association with
nondiabetic ESRD (Table 5) than with DN (Table 3,
combined analysis).
The four hits in the LIMK2-SFI1 region are all highly
correlated (Supplementary Table S4 online). SNPs rs1034589 in
RNF185, rs2106294 in LIMK2, and rs4820043 also in LIMK2 are
all perfectly correlated with one another (r2¼ 1.0, Supplemen-
tary Table S4 online). In addition, these SNPs are all highly
correlated with rs5749286 in SFI1 (r2¼ 0.85, Supplementary
Table S4 online). However, the LIMK2-SFI1 region and the
MYH9 region are poorly correlated with r2 values ranging from
0.0324 to 0.0335 (Supplementary Table S4 online).
Tests for association of previously identified nephropathy
genes
In previous studies,7,8,10–12,18–23 multiple loci have been
implicated in different ethnicities with either renal failure
or renal function in both diabetic and nondiabetic patients.
We have assessed association with many of these genes (such
as PVT1, FRMD3, CARS, ACACB, NEDD4L, SERPINB7,
CNDP1, CNDP2, ELMO1, SHROOM3, UMOD, GATM-
SPATA5L1, GCK2, ALMS1, DAB2, SLC34A1, VEGFA,
SLC22A2, PRKAG2, STC1, ATXN2, DACH1, SLC7A9) and
T2DM-ESRD in our GWAS. For each locus, the entire genic
region, along with 10 kb upstream and downstream of the
gene, was inspected for association in the GWAS data to see
whether other variants in the same gene were associated with
T2DM-ESRD in AAs. All of these results are presented in
Supplementary Table S5 online. Although there are some
results that are nominally significant, none of the results meet
a Bonferroni correction (P¼ 0.05/1909 total SNPs¼ 2.6 105)
with the lowest P-value for this analysis being 5.8 104 in the
NEDD4L gene.
DISCUSSION
We performed a high-density GWAS to investigate genetic
susceptibility to T2DM-ESRD and all-cause ESRD in AAs.
Previous GWASs for diabetes-associated nephropathy in
Japanese,7 Pima Indians,8 and CAs 9 have identified several
potential DN loci: ELMO1,7 PVT1,8 FRMD3, and CARS.9 We
have previously observed association with the ELMO1 and
MYH9 genes and T2DM-ESRD in our AA population.17,20
These studies in other ethnicities have used a study design of
comparing cases with T2DM-ESRD and controls with T2DM
and no nephropathy. Although this study design might be
appropriate for other ethnicities, it has serious limitations for
AAs. AAs with T2DM and preserved renal function for X10
years (‘hypernormal’ controls) are perhaps the ideal control
group, but are rare.24 We estimate that o10% of AA T2DM
affected patients of 10 years duration have preserved renal
function. We have chosen a study design that is flexible
and support studies of T2DM and body mass index in
parallel with T2DM-ESRD. Importantly, we have used both
replication and several contrast groups to differentiate
between T2DM-ESRD and T2DM. This system works quite
well: the strongest T2DM-associated gene in AAs is TCF7L2,
which is easily filtered out of our hits for T2DM-ESRD, but
prominently associated with T2DM.25,26
We identified five novel gene regions with evidence of
association with T2DM-ESRD in AAs (Po1.0 105):
SASH1, RPS12, AUH, MSRB3-HMGA2, and LIMK2-SFI1.
One of these regions, LIMK2-SFI1, was also significantly
associated (Po5.0 108) with all-cause ESRD. MYH9,
which has been previously associated with nondiabetic
nephropathy,14–16 and DN,17 also showed significant associa-
tion (Po5.0 108) with all-cause ESRD.
SASH1, located at 6q24.3, encodes the sterile a-motif
(SAM)- and SH3-domain containing 1 protein and is
ubiquitously expressed. SASH1 was originally identified as a
candidate tumor-suppressor gene, being downregulated in
the majority (74%) of breast cancer tumors,27 and has been
shown to be downregulated in colon cancer.28 SASH1 also
functions as a signaling adapter, as a downstream target in
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Figure 2 |All-cause ESRD candidate regions. (a) LIMK2-SFI1
gene region. (b) MYH9 gene region. log10 PADD values from the
GWAS are plotted versus position (genome build 36). The large
red diamond indicates PADD values from the GWAS of the
marker(s) displayed. The large blue diamond and corresponding
P-value indicates PADD values from the combined analysis of the
marker(s) displayed. LD based on control samples is color coded:
red (r2 to top SNP 0.8–1.0), orange (0.5–0.8), yellow (0.2–0.5), and
white (o0.2). Gene annotations were obtained from UCSC
Genome Browser (RefSeq Genes, b36). Arrows represent direction
of transcription. ESRD, end-stage renal disease; GWAS, genome-
wide association study; LD, linkage disequilibrium; MYH9,
nonmuscle myosin heavy chain 9.
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the insulin-like growth factor-1/phosphatidylinositol
3-kinase signaling pathway.29 SNP rs6930576, located within
this gene, showed the strongest association with T2DM-
ESRD in the combined analysis, suggesting that this gene may
also have a role in the progression of DN.
Two other candidate regions are also worth mentioning.
The ribosomal protein S12 gene (RPS12) is located on
chromosome 6q23.2. The protein encoded by this gene is
located in the cytoplasm and is a component of the 40S
ribosomal subunit.30 RPS12 is also a potential target gene of
microRNA-377, which has been consistently upregulated in
in vitro DN models and in in vivo DN mouse models.31 If
RPS12 is also upregulated in the diabetic milieu, it may
contribute to the progression of DN.
LIMK2, LIM kinase 2, is located on chromosome 22 at
22q12.2.32 There are three isoforms of LIMK2 produced by
alternative splicing: variants 1, 2a, and 2b.33 LIMK2 is one of
two members of the LIM kinase family, and contains two
LIM domains at the N terminus and a protein kinase domain
at the C terminus.32 LIMK2 is activated by Rho and Cdc42 by
ROCK and PAK, respectively; in turn, LIMK2 phosphorylates
cofilin, eliminating cofilin’s ability to bind and depolymerize
actin. This leads to an accumulation of actin filaments and
aggregates. It is through this action that LIMK2 has a role in
the Rho- and Cdc42-induced reorganization of the actin
cytoskeleton.34–36 LIMK2 is widely expressed in all tissues,37
showing moderate expression in the kidney.32,37 Homozy-
gous Limk2 gene-deficient mice (Limk2/), created using a
Cre-mediated excision to disrupt all three LIMK2 isoforms,
exhibited normal growth to adulthood when compared with
wild-type and heterozygous mice.38 However, Limk2/ mice
had moderate kidney abnormalities with dilated collecting
tubules and slight decreases in the number of glomeruli,
without changes in nephron function.38 If variants in LIMK2
lead to kidney abnormalities in humans, this may be
detrimental in a diabetic environment, and could possibly
lead to progression of DN. This would also support LIMK2 as
a potential all-cause ESRD candidate locus.
The other gene in the LIMK2 region that showed evidence
of association with T2DM-ESRD and all-cause ESRD was
SFI1, Sfi1 homolog, spindle assembly-associated (yeast). In
yeast, SFI1 has been shown to be an essential and conserved
component of centrosomes—known as spindle pole bodies in
yeast.39 In addition, SFI1 was shown to be required for
spindle pole body duplication and may be required for
separation of the duplicated spindle pole bodies.40
MYH9, which showed evidence of association with
T2DM-ESRD and all-cause ESRD in our study, has been
previously associated with non-T2DM nephropathy14–16 and
with diabetic forms of nephropathy.17 It should be noted that
the results reported in this study are in reference to the minor
(less frequent) allele, and are associated with protection. This
remains consistent with previous associations in which the
reported risk allele corresponded to the major allele.14–17 In
Yoruba (YRI) samples in HapMap, the protective allele for
rs735853 is observed in only 3% of chromosomes, whereas it
is seen in 457% of CEU chromosomes. For our AA sample,
the allele frequencies are 0.082 for cases and 0.123 for
controls. This result may reflect a selection for the admixed
European allele, or more broadly, for the European locus,
which provides protection in AAs. Whether this reflects that
some cases in our study could be non-diabetic ESRD
(Freedman et al.17: recently re-estimated to be 13%) or
reflects a role for this allele in T2DM-ESRD remains to be
determined. Parenthetically, the LIMK2-SFI1 gene region is
located B5 Mb away from the MYH9 gene region. We
evaluated linkage disequilibrium across chromosome 22
(Supplementary Table S4 online). The SNPs that showed
evidence of association in the LIMK2-SFI1 gene region were
poorly correlated (r2p0.03) with the SNP that showed
evidence of association in MYH9, suggesting that these are
independent signals.
However, MYH9 and LIMK2 are both involved in the
reorganization and maintenance of the actin cytoskeleton.
MYH9 encodes the nonmuscle myosin heavy chain IIA,
which is highly conserved and similar to other nonmuscle
myosins.41,42 Myosin IIA is expressed in podocytes and
mesangial cells.41 Within the podocyte, myosin IIA localizes
to the foot process in which it is involved in the movement of
actin filaments to maintain cell structure.43 Many studies
have shown that mutations in MYH9 are associated with
kidney disease.14–17 As LIMK2 is in the same pathway, it
remains possible that mutations in LIMK2 could produce
kidney disease; thus, LIMK2 is a strong candidate in T2DM-
ESRD and all-cause ESRD.
We performed two further assessments of loci in this
study. First, we assessed several of the AA loci (13/25) to test
whether they contributed to T2DM-ESRD in a sample of CA
cases and controls. We observed no evidence for association
in CAs (data not shown), but a more comprehensive, better-
powered experiment might be more definitive. Conversely,
we did not observe evidence of association with any of the
DN and chronic kidney disease candidate genes and
T2DM-ESRD in AAs in the current study. The GWAS herein
did not interrogate some of the specific disease associated
SNPs such as ACACB SNP rs2268388 with which we
previously reported evidence of association.21 The large
number of SNPs evaluated in this study (41900) results in a
more stringent threshold for significance. As these variants
were mainly identified in non-African derived racial/ethnic
groups, they may have a limited role in the development of
T2DM-ESRD in AAs.
This study has similar limitations as other GWAS.
Although we have identified 25 variants that may influence
T2DM-ESRD in 19 candidate regions, none of these regions
have reached genome-wide significance (Po5.0 108) with
the T2DM-ESRD phenotype. However, even though this
study has a limited sample size for the GWAS discovery
phase, power calculations (Supplementary Table S6 online)
show that we have moderate statistical power to detect ORs
of 1.3 (minor allele frequency¼ 0.35), consistent with
previously published effect sizes for DN (FRMD3 and CARS,
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OR¼ 1.45 and OR¼ 1.36, respectively9). In addition, other
phases of the study: replication, trait discrimination, and all-
cause ESRD analysis have excellent power for detecting
association, given the goals of each step (for example,
nominal association in replication; P-valuep1 106 for the
all-cause ESRD analysis). There are almost certainly addi-
tional loci of moderate effect that have not been captured in
this study, and loci of weaker effect will require a significantly
larger study. There are few other existing collections of
appropriate samples in AAs, and we are one of the few centers
with active recruiting efforts in this population. This will
make the search for additional replication populations more
difficult. In addition, it is difficult to ensure that all subjects
clinically labeled as having T2DM-ESRD lack other renal
lesions. This difficulty plagues all studies of DN and we chose
inclusion criteria similar to other large studies.44
In conclusion, we performed a GWAS for T2DM-ESRD in
AAs. We then carried out a replication phase and a trait
discrimination phase to determine whether associations were
with T2DM, T2DM-ESRD, and/or all-cause ESRD. Through
these studies, we have discovered 25 potential variants in 19
genes associated with T2DM-ESRD, including SASH1,
RPS12, AUH, MSRB3-HMGA2, and LIMK2-SFI1. These
results require further replication to confirm their role in
T2DM-ESRD susceptibility and to clarify their role in all-
cause ESRD in AAs.
MATERIALS AND METHODS
Subjects
GWAS samples and clinical characteristics. Recruitment and
sample collection procedures were approved by the Institutional
Review Board at Wake Forest University, and informed consent was
obtained from all study participants. Patients with T2DM were
recruited from dialysis facilities. Individuals with a history of
ketoacidosis or those who developed diabetes before the age of 25
years and received continuous insulin therapy since diagnosis were
assumed to have type 1 diabetes and were excluded. T2DM was
diagnosed in AAs who reported developing diabetes after the age of
25 years and who did not receive only insulin therapy since
diagnosis. Cases had T2DM diagnosed at least 5 years before
initiating renal replacement therapy, background or greater diabetic
retinopathy, and/or X100 mg/dl proteinuria on urinalysis in the
absence of other causes of nephropathy (T2DM-ESRD subjects).
Unrelated AA controls without a current diagnosis of diabetes or
renal disease were recruited from the community and internal
medicine clinics (control subjects). All cases and nondiabetic,
nonnephropathy controls were born in North Carolina,
South Carolina, Georgia, Tennessee, or Virginia. DNA extraction
was performed using the PureGene system (Gentra Systems,
Minneapolis, MN).
Replication study samples and clinical characteristics. In-
formed consent was obtained from all study participants, and
recruitment and sample collection procedures were approved by the
Institutional Review Board at Wake Forest University. AA T2DM-
ESRD cases and nondiabetic, nonnephropathy controls were
recruited using the same criteria as the case and control subjects
that were used in the GWAS. DNA extraction was performed using
the PureGene system.
T2DM, nonnephropathy and non-T2DM-ESRD study samples,
and clinical characteristics. Sample collection procedures and
recruitment were approved by the Wake Forest University Institutional
Review Board. Informed consent was obtained from all study
participants. Subjects with T2DM without evidence of nephropathy
were recruited from medical clinics, churches, health fairs, and
community resources (T2DM subjects). Patients who had ESRD
attributed to hypertension or primary glomerular disease were
recruited (non-T2DM-ESRD subjects). Putative hypertension-asso-
ciated ESRD was diagnosed in patients with high blood pressure
preceding the initiation of renal replacement therapy and low-level
proteinuria (p30 mg/dl on urine dipstick, o0.5 g protein/24 h on
timed urine collection, or urine protein: creatinine ratioo0.5 g/g) or in
the absence of measures of proteinuria. Chronic glomerular disease-
associated ESRD was diagnosed in nondiabetic subjects with renal
biopsy evidence of primary glomerular disease (for example, focal
segmental glomerulosclerosis), proteinuriaX0.5 g/24 h, orX100 mg/dl
on urinalysis. Individuals with DN (as described above), cystic renal
diseases, hereditary nephritis, or urologic causes of ESRD were
excluded. Individuals were unrelated and self-described AA. All subjects
were born in North Carolina, South Carolina, Georgia, Virginia, or
Tennessee. The PureGene system was used for DNA extraction.
Sample preparation, genotyping, and quality control
Genome-wide association study. Genotyping was performed
at the Center for Inherited Disease Research (CIDR) using 1 mg of
genomic DNA (diluted in 1 TE buffer and at 50 ng/ml) on the
Affymetrix Genome-Wide Human SNP array 6.0 (Affymetrix, Santa
Clara, CA). DNA from cases and controls were equally interleaved
on 96-well master plates to ensure technical uniformity during
sample processing. To confirm sample identity, an SNP barcode (96
SNPs) was generated before genotyping on the Affymetrix array and
was confirmed on downstream-released genotyping data. Genotypes
were called using Birdseed version 2; Affymetrix Power Tools (APT)
1.10.0 (Affymetrix) by grouping samples by DNA plate to determine
the genotype cluster boundaries. All autosomal SNPs (n¼ 868,157)
were included in the analysis but were classified on data quality. The
primary inference was drawn from SNPs that had o5% missing
data, Hardy–Weinberg P-values in cases 40.0001 and in controls
40.01, no significant difference in missing data rate between cases
and controls and were polymorphic (n¼ 832,357). The average
sample call rate was 99.16% for all autosomal SNPs. A total of 46
blind duplicates were included in genotyping and had a con-
cordance rate of 99.59%. In addition, individuals whose gender call
from X-chromosome genotype data was discordant with the gender
obtained from patient interviews were excluded from the analysis
(n¼ 1). Cryptic relatedness was estimated by pairwise identity-by-
descent analysis implemented in the PLINK analysis software
package (http://pngu.mgh.harvard.edu/purcell/plink/).45 Two dupli-
cate samples were identified, and one sample in each duplicate pair
was removed. In addition, 104 individuals from pairs of samples
were identified as cryptic first-degree relatives; these individuals
were kept for the analysis. We also assessed heterozygosity by
estimating the inbreeding coefficient, F, using PLINK. One subject
had an F-value44 s.d. from the mean, suggesting population
substructure. This subject was removed. Our final data set consisted
of 1994 individuals (965 T2DM-ESRD cases and 1029 controls) in
which we performed association analysis.
Replication. The replication population was recruited under
identical ascertainment criteria to that of the GWAS. A total of 724
SNPs were genotyped using the iPLEX Sequenom MassARRAY platform
570 Kidney International (2011) 79, 563–572
or ig ina l a r t i c l e CW McDonough et al.: GWAS in diabetic ESRD
(Sequenom, San Diego, CA). Genotyping efficiency was 490% and 45
blind duplicates were included to ensure genotyping accuracy.
Trait discrimination. A total of 67 SNPs were genotyped using
the iPLEX Sequenom MassARRAY platform. Genotyping efficiency
was 490%. A total of 50 blind duplicates were included to ensure
genotyping accuracy.
Analysis
Genome-wide association study. To address the effect of
admixture in this AA data set, we performed a principal components
analysis, which used all high-quality data from the GWAS and
excluded regions of high linkage disequilibrium and inversions. This
approach is an iterative process whereby high-quality autosomal
SNPs (n¼ 832,357) are used to calculate the top 50 principal
components. Once calculated, the principal components are
examined to determine whether they are tied to a region of the
genome. If so, those SNPs are excluded and the analysis is repeated.
The first principal component (PC1) explained the largest propor-
tion of variation at 22%. A direct comparison of principal
components analysis with frequenist estimation of individual
ancestry proportion analysis of 70 ancestry informative markers
resulted in a high correlation between PC1 and the ancestry
informative markers (r2¼ 0.87). Other principal components were
associated with regions of the genome, representing another
unclassified source of variance, and did not further reduce the
inflation factor. The mean (s.d.) African ancestry proportions in 965
T2DM-ESRD cases and 1029 controls were 0.80±0.11 and
0.78±0.11, respectively, as estimated by Frequentist Estimation of
individual ancestry proportion analysis.46 To test for association
with T2DM-ESRD, genotypic tests of association were performed on
each SNP individually using SNPGWA version 4.0 (http://www.
phs.wfubmc.edu),47 an analytic package that includes the capability
to perform association calculations adjusting for covariates. The
genotypic association reported in this study is for analyses
incorporating adjustment for PC1. The primary inference is based
on the additive genetic model. The inflation factor was calculated
from the observed mean w2 statistic across high-quality autosomal
SNPs (n¼ 832,357). Under the null hypothesis, if there is no
inflation, the expected mean value is 1. In our population, the
inflation factor calculated in the GWAS sample with 104 cryptic-
related individuals (n¼ 1994), adjusting for PC1 was 1.06. After 54
subjects were removed to eliminate the cryptic relations (n¼ 1940), the
inflation factor in the GWAS, adjusting for PC1 was 1.04. With this
minimal improvement in inflation, all subjects (n¼ 1994) were retained
for analysis as the difference between the inflation factors is only 0.02.
Replication in T2DM-ESRD cases and nondiabetic, nonnephrop-
athy controls. To account for admixture in the replication cohort,
ancestral allele frequencies were estimated from the results of the 70
ancestry informative markers genotyped in 44 Yoruba Nigerians and
39 European Americans. Individual ancestral proportions were
generated for each subject using frequenist estimation of individual
ancestry proportion, an EM algorithm, under a two-population
model. The mean (s.d.) African ancestry proportions in 709 T2DM-
ESRD cases and 690 controls were 0.80±0.12 and 0.76±0.13,
respectively. Association analysis was performed as described for the
GWAS.
Combined analysis of T2DM-ESRD cases and nondiabetic,
nonnephropathy controls. The GWAS and replication cohorts were
merged as one cohort for a combined analysis. Admixture in the
combined cohort was accounted for by using ancestral allele frequencies
as described for the replication analysis. The association analysis was
performed as described for the GWAS and replication study.
Discrimination between T2DM-ESRD, T2DM, and all-cause
ESRD. To determine the association with T2DM-ESRD, T2DM,
and/or all-cause ESRD, additional association analyses were
performed as described for the GWAS, replication, and combined
analysis incorporating the 1246 T2DM, nonnephropathy subjects
and the 1216 non-T2DM-ESRD subjects. Admixture was accounted
for through ancestral allele frequencies as described in the
replication and combined analysis. The mean (s.d.) African ancestry
proportions in 1246 T2DM, nonnephropathy cases and 1216 non-
T2DM-ESRD cases were 0.76±0.13 and 0.79±0.12, respectively.
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